Provided by Tiger Trade Technology Pte. Ltd.

Omeros

18.69
-0.0600-0.32%
Volume:582.53K
Turnover:10.97M
Market Cap:1.35B
PE:11.90
High:19.47
Open:18.97
Low:18.44
Close:18.75
52wk High:19.65
52wk Low:3.94
Shares:72.38M
Float Shares:67.73M
Volume Ratio:0.60
T/O Rate:0.86%
Dividend:- -
Dividend Rate:- -
EPS(TTM):1.57
EPS(LYR):-0.0527
ROE:-576.33%
ROA:-18.68%
PB:-26.34
PE(LYR):-354.33

Loading ...

Omeros Maintained at Buy as Strong YARTEMLEA Launch and Reduced C5 Competition Support Unchanged $33 Price Target

TIPRANKS
·
Aug 13

Omeros Jumps on Surprise Quarterly Profit

Reuters
·
Aug 13

Omeros Swings to Q2 Adjusted Earnings; Shares up

MT Newswires Live
·
Aug 13

Omeros Corporation Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 13

Omeros Q2 2026 Earnings: YARTEMLEA Drives Operating Break-Even

TradingKey
·
Aug 13

Omeros Q2 Yartemlea Net Revenue Jumps 190%

Reuters
·
Aug 13

Omeros Q2 Adj. EPS $0.02 Beats $(0.27) Estimate, Sales $28.529M Beat $12.700M Estimate

Benzinga Earnings
·
Aug 13

Omeros Corporation Q2 EPS USD 0.18

THOMSON REUTERS
·
Aug 13

Omeros Corporation Expected to Post a Loss of 27 Cents a Share - Earnings Preview

Reuters
·
Aug 11

Press Release: Omeros Corporation to Announce Second Quarter Financial Results on August 12, 2026

Dow Jones
·
Aug 10

Omeros to Report Q2 Results, Host Earnings Call

Reuters
·
Aug 10

Omeros grants new technology add-on payment status to Yartemlea

TIPRANKS
·
Aug 03

Omeros Corp - Eligible Hospitals to Receive Additional Medicare Reimbursement for Yartemlea from October 1, 2026

THOMSON REUTERS
·
Aug 03

Omeros Corp - CMS Grants Ntap Status for Yartemlea Under Fy2027 Ipps Final Rule

THOMSON REUTERS
·
Aug 03

Analysts Offer Insights on Healthcare Companies: Argenx Se (ARGX) and Omeros (OMER)

TIPRANKS
·
Jul 27

Omeros Buy Rating Reiterated as Ultomiris Setback Eases Competitive Risk; $33 Price Target Maintained

TIPRANKS
·
Jul 27

AstraZeneca miss ‘clear positive’ for Omeros, says H.C. Wainwright

TIPRANKS
·
Jul 27

Omeros up 11% to $10.89 after AstraZeneca study failure

TIPRANKS
·
Jul 27

Omeros Reduces Convertible Debt Through Note Repurchases

TIPRANKS
·
Jul 21

Omeros Repurchases USD 14.5 Million of 9.5% Convertible Notes Due 2029 for USD 29 Million

Reuters
·
Jul 21